TY - JOUR
T1 - Risk factors for the development of auditory toxicity in patients receiving aminoglycosides
AU - Moore, R. D.
AU - Smith, C. R.
AU - Lietman, P. S.
N1 - Funding Information:
Received for publication May 25, 1983, and in revised form August 19. 1983. This work was supported in part by funds from the Henry J. Kaiser Family Foundation and Eli Lilly Co. Dr Moore is a Henry J. Kaiser Family Foundation fellow in Internal Medicine. Please address requests for reprints to Dr Richard D. Moore, Harvey 502, The John Hopkins Hospital. 600 North Wolfe Street, Baltimore, Maryland 21205.
PY - 1984
Y1 - 1984
N2 - Risk factors for the development of auditory toxicity in patients receiving aminoglycosides were determined from the analysis of 135 patients enrolled in three prospective, randomized, double-blind clinical trials of gentamicin, tobramycin, and amikacin. Auditory toxicity, defined as a decrease in auditor acuity of ≥15 dB, occurred in 30 patients (22.3%). Patients with auditory toxicity underwent therapy for a longer period, were more likely to be bacteremic, and had, on the average, a higher temperature (P < 0.05). Using stepwise discriminant analysis, we selected these factors with liver dysfunction and the serum urea nitrogen:serum creatinine ratio in a function that accurately discriminates between toxic and nontoxic patients. Factors not adding significantly to the predictive accuracy of the equation were plasma aminoglycoside levels, aminoglycoside type, furosemide use, diabetes, age, sex, renal function, initial auditory acuity, hematocrit value, and shock. This analysis may be important both for determining the pathophysiology of auditory toxicity and for the prognostic stratification of patients receiving aminoglycosides in clinical trials.
AB - Risk factors for the development of auditory toxicity in patients receiving aminoglycosides were determined from the analysis of 135 patients enrolled in three prospective, randomized, double-blind clinical trials of gentamicin, tobramycin, and amikacin. Auditory toxicity, defined as a decrease in auditor acuity of ≥15 dB, occurred in 30 patients (22.3%). Patients with auditory toxicity underwent therapy for a longer period, were more likely to be bacteremic, and had, on the average, a higher temperature (P < 0.05). Using stepwise discriminant analysis, we selected these factors with liver dysfunction and the serum urea nitrogen:serum creatinine ratio in a function that accurately discriminates between toxic and nontoxic patients. Factors not adding significantly to the predictive accuracy of the equation were plasma aminoglycoside levels, aminoglycoside type, furosemide use, diabetes, age, sex, renal function, initial auditory acuity, hematocrit value, and shock. This analysis may be important both for determining the pathophysiology of auditory toxicity and for the prognostic stratification of patients receiving aminoglycosides in clinical trials.
UR - http://www.scopus.com/inward/record.url?scp=0021365039&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021365039&partnerID=8YFLogxK
U2 - 10.1093/infdis/149.1.23
DO - 10.1093/infdis/149.1.23
M3 - Article
C2 - 6693788
AN - SCOPUS:0021365039
SN - 0022-1899
VL - 149
SP - 23
EP - 30
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 1
ER -